Meta Information

ID:semaglutide

Name:Semaglutide

Schema Version:1.5

Title

Semaglutide

Alternate Names

• Ozempic
• Wegovy
• Rybelsus

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

1000

High Cost:

1600

Cost Type:

monthly

Description:

Retail cost without insurance; compounded or international versions may be cheaper.

Summary

Semaglutide is a GLP-1 receptor agonist that mimics an incretin hormone to improve glycemic control, reduce appetite, and slow gastric emptying. Its healthspan relevance stems from its profound ability to induce weight loss and resolve metabolic dysfunction, two of the most significant drivers of age-related chronic disease.

Purpose

A GLP-1 agonist for metabolic health and weight management.

Card Summary

A GLP-1 receptor agonist that improves metabolic health and induces significant weight loss, key factors in extending healthspan.

Drug Class

glp-1-receptor-agonists

Drugs In Class

Empty Array

Impact

Score:

7.8

Justification:

Profoundly improves metabolic health and body composition, key drivers of healthspan.

Evidence

Grade:

A

Score:

9.5

Justification:

Multiple large-scale human RCTs confirm significant cardiovascular and metabolic benefits.

Safety

Score:

5.5

Justification:

Common GI side effects; requires medical supervision for rare but serious risks.

Flags

• Requires a prescription and ongoing medical supervision.
• Common side effects include nausea, vomiting, and diarrhea, especially during dose titration.
• Risk of muscle mass loss alongside fat loss; resistance training is crucial.
• Boxed warning for risk of thyroid C-cell tumors based on rodent studies.
• May interact with oral medications by delaying their absorption.
• Rare risks include pancreatitis, gallbladder problems, and gastroparesis.

Verdict

A powerful tool for metabolic health, but requires careful medical management.

Created

2026-04-24T00:09:39.539063Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

healthspan

Description:

Semaglutide is a GLP-1 receptor agonist that mimics an incretin hormone to improve glycemic control, reduce appetite, and slow gastric emptying. Its healthspan relevance stems from its profound abilit...

Typical Protocol

• Weekly subcutaneous injections starting at 0.25 mg, titrating up based on tolerance and goals.
• Daily oral tablets (Rybelsus) starting at 3 mg, titrating up as directed.
• Lower maintenance doses may be used for metabolic health benefits without aggressive weight loss.